* Allogene Therapeutics Inc is expected to show a fall in quarterly revenue when it reports results on November 7 for the period ending September 30 2024
* The South San Francisco California-based company is expected to report a 69.9% decrease in revenue to $12.93 thousand from $43 thousand a year ago, according to the mean estimate from 14 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Allogene Therapeutics Inc is for a loss of 33 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Allogene Therapeutics Inc is $9.50, above its last closing price of $2.99.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.34 -0.35 -0.35 Met -0.8
Mar. 31 2024 -0.40 -0.41 -0.38 Beat 7.2
Dec. 31 2023 -0.41 -0.45 -0.43 Beat 4.3
Jan. 1 0001 -0.51 -0.52 -0.37 Beat 28.8
Jan. -0.60 -0.59 -0.53 Beat 10
1 0001
Mar. 31 2023 -0.63 -0.62 -0.68 Missed -10.2
Dec. 31 2022 -0.66 -0.70 -0.66 Beat 5.6
Sep. 30 2022 -0.66 -0.64 -0.58 Beat 10
This summary was machine generated November 6 at 04:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments